Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUC-1-loaded dendritic cells
- Development stage
- Preclinical
- Lead developer
- Third Military Medical University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
01
Overview
MUC-1-loaded dendritic cells is an autologous dendritic cell immunotherapy being developed by the Third Military Medical University and Xinqiao Hospital for the treatment of non-small-cell lung cancer (NSCLC). The therapy consists of patient-derived dendritic cells loaded with Mucin-1 (MUC-1) peptide antigens. When administered, these antigen-presenting cells stimulate a targeted T-cell-mediated immune response against MUC-1-expressing tumor cells. It has been evaluated in clinical trials in China in combination with radiotherapy for patients with middle or late-stage NSCLC.
- Other names
- MUC-1 peptide-loaded dendritic cellsMUC1 peptide-loaded dendritic cellsMUC 1 peptide-loaded dendritic cellsMUC-1-loaded dendritic cell immunotherapyMUC1-loaded dendritic cell immunotherapyMUC 1-loaded dendritic cell immunotherapyMUC-1-loaded dendritic cell vaccineMUC1-loaded dendritic cell vaccineMUC 1-loaded dendritic cell vaccine
02
Targets
MHC I (MHC class I})MRC1 (Mannose Receptor C-type 1)γδ TCR (T-cell receptor)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on MUC-1-loaded dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUC-1-loaded dendritic cells.